Syverson Strege & Co’s Zevra Therapeutics ZVRA Stock Holding History

Syverson Strege & Co’s Portfolio ZVRA Stock Details ZVRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-734	Closed	-$4.04K	–	646
2023 Q1	$4.04K	Hold	734	–	–	﹤0.01%	374
2022 Q4	$3.37K	Hold	734	–	–	﹤0.01%	243
2022 Q3	$5K	Hold	734	–	–	﹤0.01%	215
2022 Q2	$3K	Hold	734	–	–	﹤0.01%	288
2022 Q1	$4K	Hold	734	–	–	﹤0.01%	253
2021 Q4	$6K	Hold	734	–	–	﹤0.01%	231
2021 Q3	$7K	Hold	734	–	–	0.01%	288
2021 Q2	$9K	Hold	734	–	–	0.01%	206
2021 Q1	$7K	Buy	+734	New	+$6.41K	0.01%	210

Other funds holding ZVRA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Janney Montgomery Scott Philadelphia, Pennsylvania $51.6B AUM 27.34% 1-Year Est. Return

RPCONE

Retirement Planning Company of New England Warwick, Rhode Island $278M AUM 38.65% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

MAM

Mystic Asset Management Warwick, Rhode Island $468M AUM 30.94% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Syverson Strege & Co's ZVRA Position: Q2 2023 in Review

Syverson Strege & Co sold out of Zevra Therapeutics (ZVRA) in Q2 2023, closing a stake of 734 shares — an estimated $4.04K sold.

Syverson Strege & Co first reported a position in ZVRA in Q1 2021 and held it in 9 quarters. The position peaked at $9K in Q2 2021. 71 funds tracked by Wall St. Rank hold ZVRA as of Q2 2023.

Syverson Strege & Co reported no remaining Zevra Therapeutics position as of Q2 2023 after selling out during the quarter.
Syverson Strege & Co sold 734 Zevra Therapeutics shares in Q2 2023, an estimated $4.04K.
Syverson Strege & Co first reported a position in Zevra Therapeutics in Q1 2021 and held it in 9 quarters.
Syverson Strege & Co's Zevra Therapeutics position peaked at $9K in Q2 2021.
71 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q2 2023.

Based on Syverson Strege & Co's 13F filing for Q2 2023, filed 4 Aug 2023.